Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684265 | 0.86 | MMP1 (0.43) | MAPTTP53RXFP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6791261 | 0.84 | TRPA1 (0.54) | MAPTALDH1A1HTTSMN1; SMN2KDM4E | |
| SCHEMBL7120749 | 0.81 | MAPT (0.46) | MAPTTP53RXFP1ROCK2ALDH1A1 | |
| SCHEMBL6684431 | 0.80 | KMT2A (0.49) | MAPTTP53RXFP1ALDH1A1HTT | |
| SCHEMBL6678512 | 0.80 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2MMP13RAB9AHPGD | |
| SCHEMBL6474162 | 0.77 | MAPT (0.56) | MAPTTP53RXFP1ROCK2ALDH1A1 | |
| SCHEMBL6680234 | 0.77 | MAPT (0.48) | MAPTTP53RXFP1ALDH1A1HTT | |
| SCHEMBL6682687 | 0.76 | MAPT (0.46) | MAPTTP53RXFP1ROCK2ALDH1A1 | |
| SCHEMBL6679503 | 0.76 | TRPA1 (0.42) | MAPTTP53RXFP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6679546 | 0.74 | TRPA1 (0.43) | ALDH1A1HTTSMN1; SMN2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | MAPT 1473/4885TP53 2986/4885RXFP1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.